Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2020; 66(5): 17-22

THE EFFECT OF PROTEASE-ACTIVATED RECEPTORS 1 INHIBITION ON DEPRESSIVE-LIKE BEHAVIOR IN THE LATENT STAGE OF FORMATION OF TEMPORAL LOBE EPILEPSY

М. Semenikhina, M. Fedoryuk, R. Bogovik

    O.O.Bogomoletz Institute of Physiology of NAS of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz66.05.017


Abstract

Here we investigate the effect of pharmacological blockade of protease-activated receptors 1 (PAR1) on depressive-like behavioral impairments following status epilepticus (SE). Behavioral tests were performed during the latent stage of formation of temporal lobe epilepsy two weeks after SE induced using lithium-pilocarpine model. The PAR1 blocker (SCH 79797) was injected for 10 days after SE. The results indicate a partial normalization of depressive-like behavior in the forced swim test: the climbing time was 180 s after PAR1 inhibition, and 87 s after SE). We also observed behavioral normalization after PAR1 inhibition in the sucrose test. PAR1 inhibition led to the normalization of climbing time in the forced swim test, as well as normalized the behavior in the sucrose preference test. At the same time, the swimming time in the forced swim test decreased due to the PAR1 inhibition compared to the control group, while the floating time increased.

Keywords: status epilepticus; latent stage of epilepsy formation; protease-activated receptors 1; PAR1; depression.

Full text: (PDF, in Ukrainian)

References

  1. Gilliam F, Kanner AM. Treatment of depressive disorders in epilepsy patients. Epilepsy Behav. 2002;3:2-9. CrossRef
  2. Kanner AM. Depression in epilepsy: Prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiat. 2003;54:388-98. CrossRef
  3. Kanner AM. Depression and Epilepsy: A new perspective on two closely related disorders. Curr Rev Clin Sci. 2008;8:85-9.
  4. Hermann BP, Seidenberg M, Bell B. The neurodevelopmental impact of childhood onset temporal lobe epilepsy on brain structure and function and the risk of progressive cognitive effects. Prog Brain Res. 2002;135:429-38. CrossRef
  5. Forsgren L, Nyström L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res. 1990;6:66-81. CrossRef
  6. Bogovik R, Fedoriuk M, Isaev D, Krishtal O, Holmes GL, Isaeva E. Effects of protease-activated receptor 1 inhibition on anxiety and fear following status epilepticus. Epilepsy Behav. 2017;67:66-9. CrossRef PubMed
  7. Semenikhina M, Bogovyk R, Fedoriuk M, AlKury LT, Savotchenko A, Krishtal O, et al. Inhibition of proteaseactivated receptor 1 ameliorates behavioral deficits and restores hippocampal synaptic plasticity in a rat model of status epilepticus. Neurosci Lett. 2019; 692:64-8. CrossRef PubMed
  8. Semenikhina M, Bogovik R, Fedoryuk M, Lunko O, Savotchenko A, Isaeva E. Pharmacological blockade of protease-activated receptors 1 normalizes behavioral hyperexcitability of rats in the latent stage of the experimental model of temporal lobe epilepsy. Fiziol Zh. 2019;65(3):7-11. CrossRef
  9. Racine RJ. Modification of seizure activity by electrical modification of after-discharge. Electroencephalogr Clin Neurophysiol. 1972;32:281-94. CrossRef
  10. West CHK, Weiss JM. Effects of antidepressant drugs on rats bred for low activity in the swim test. Pharmacol Biochem Behav. 1998;61:67-79. Bokoch MP, Zou Y, Rasmussen SGF, Liu CW, Nygaard R, Rosenbaum DM, et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature. 2010;463:108-12. CrossRef PubMed PubMedCentral
  11. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007. CrossRef PubMed
  12. Traynelis SF, Trejo J. Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol. 2007;14:230-5. CrossRef PubMed
  13. Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord. 2009;11:1-9. CrossRef PubMed
  14. Shen Y, Peng W, Chen Q, Hammock BD, Liu J, Li D, et al. Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model. Brain Behav Immun. 2019;81:535-44. CrossRef PubMed PubMedCentral
  15. Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R. Depression after status epilepticus: Behavioural and biochemical deficits and effects of fluoxetine. Brain. 2008;131:2071-83. CrossRef PubMed PubMedCentral
  16. Lunko OO, Bogovyk RI, Fedoriuk MP, Semenets GS, Isaeva E V. The protease-activated receptor 1 inhibition during epileptogenesis does not alter behavioral excitability in rats. Fiziol Zh. 2018;1:12-8. CrossRef
  17. Dos Santos JG, Longo BM, Blanco MM, Menezes de Oliveira MG, Mello LE, Guilherme J, et al. Behavioral changes resulting from the administration of cycloheximide in the pilocarpine model of epilepsy. Brain Res. 2005;1066:37-48. CrossRef PubMed
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.